Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab in Functional Hypothalamic Amenorrhea
NCT06533865Phase 3Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2025
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of romosozumab in Functional hypothalamic amenorrhea (FHA), sponsored by Massachusetts General Hospital. Started Mar 2025; status: recruiting.
02
Drugs
romosozumab
03
Conditions
Functional hypothalamic amenorrhea (FHA)
Beyond the preview
Go deeper on NCT06533865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533865.